{
  "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
  "docSlug": "e5f34198aff4080f2687fe569caff4c0",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 33,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/29",
  "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
  "deckJsonHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761.json",
  "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.29
      },
      "kind": "diagram",
      "text": "2022, 2023, 2024",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56b320b0-8d72-442f-a514-f9729cbbd729",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.66,
        "y": 0.45
      },
      "kind": "list",
      "text": "Neurofilament Results; Biomarker Results; ALS End of Phase 2 Meeting with the FDA and EMA; Initiate ALS Phase 3 clinical study as needed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73924662-37df-4402-bbef-50b1150edf95",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "list",
      "text": "Initiated ALS Phase 2b PARADIGM study; Received FDA IND Clearance for PrimeC; Completed PK study single-dose & multi-dose successfully; Completed In-life 90-day GLP toxicology study successfully",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dfe5847-052d-46da-b97d-7ff3a35b8d0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "list",
      "text": "Completed Alzheimer's biomarker study with positive results; Completed Parkinson's biomarker study with positive results; Type D Meeting with the FDA; Release ALS Phase 2b clinical study top-line results; Initiated Alzheimer's Phase 2 study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5d8d6de-011b-401c-b4cd-bea7f84a3a17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "Milestones Achieved and Upcoming Potential Catalysts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5d590e1-da1a-4bee-b2ec-d51277b9b270",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "4502401f-0048-4bde-95f7-0d12e30a0d5f",
      "evidence": "Chronological progression of company milestones",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}